Longevity Lab Report
← All supplements

Sermorelin

A growth-hormone signal with a pediatric past; the adult longevity file is small, old, and surrogate-only.

D

Evidence grade

D

Worth it

$100-300/month

Typical cost

DoseThe marketed adult regimen is typically 200 to 500 micrograms by subcutaneous injection at night, five to seven nights a week, per telehealth provider listings. That regimen comes from clinic practice, not from an adult trial; no dose is established for any adult use.

BasisThe human evidence is almost entirely pediatric, where sermorelin raised growth velocity in growth-hormone-deficient children.

Sermorelin is a synthetic copy of the first 29 amino acids of growth-hormone-releasing hormone. We grade Sermorelin D on evidence and D for worth-it at about $100-300 per month.

What it does

Sermorelin is a synthetic copy of the first 29 amino acids of growth-hormone-releasing hormone. It prompts the pituitary to release the body's own growth hormone in pulses. It was FDA-approved as Geref for diagnosing growth hormone deficiency (1990) and for treating children with growth failure from inadequate growth hormone secretion (1997); the manufacturer discontinued it in 2008 and the approvals were withdrawn in 2009, with the FDA determining in 2013 that the withdrawal was not for safety or effectiveness reasons. Today it is sold to adults by telehealth clinics as a compounded injection for sleep, body composition, and longevity, uses no regulator has approved and no adult outcome trial has tested.

What the research says

  • Raises growth hormone and IGF-1 in adults

    Evidence: moderate. Demonstrated in small adult studies of GHRH(1-29): the pituitary responds and IGF-1 rises. This is a surrogate finding; no adult outcome benefit has been shown to follow from it.

  • Improves sleep, body composition, and recovery in adults (the marketed uses)

    Evidence: unsupported. No randomized adult outcome trial supports these uses. The marketing rests on the hormone rise above and on the pediatric record, neither of which is evidence for them.

The human evidence is almost entirely pediatric, where sermorelin raised growth velocity in growth-hormone-deficient children. In adults, the file is a handful of small 1990s studies of GHRH(1-29) showing growth hormone and IGF-1 rising, with occasional lean-mass signals, and no trial powered for any outcome an adult buying it cares about: not sleep quality, not strength, not body composition at a meaningful horizon, not longevity. The Endocrine Society's guidance recognizes no growth-hormone-axis therapy approved for anti-aging. A drug can be genuinely approvable for a narrow pediatric indication and still carry an empty adult file; that is this record.

Is it worth it?

DWorth it

At $100 to $300 a month for a compounded injection, the buyer is paying a drug price for an untested use: the adult outcome file is empty, the hormone rise it reliably produces has no demonstrated benefit attached, and the regulatory position offers no approval behind the marketing. The derivation agrees: an evidence grade of D sits below the worth-it model's gated pool.

Typical cost

$100-300/month

Common form, not a brand recommendation

Dosage context emerging

The marketed adult regimen is typically 200 to 500 micrograms by subcutaneous injection at night, five to seven nights a week, per telehealth provider listings. That regimen comes from clinic practice, not from an adult trial; no dose is established for any adult use.

The worth-it ranking

Sermorelin sits outside the worth-it ranking of 38.

Sermorelin sits outside that ranking of 38. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.

  1. 1AWorth itCreatine evidence A-~$5-10/mo
  2. 2AWorth itCaffeine evidence B+~$5-10/mo
  3. 3AWorth itVitamin D evidence B~$5-8/mo

See the full ranking of 38 →

When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.

Safety notes

Short-term tolerability in the pediatric and small adult literature is generally acceptable, with injection-site reactions, flushing, and headache the common reports; the long-term adult safety file is thin because the adult trials are few and short. Raising growth hormone is not a neutral act: excess growth hormone signaling carries metabolic and proliferative concerns, which is why the Endocrine Society recognizes no anti-aging use. Sermorelin is prohibited in sport at all times (WADA S2). Regulatory position, verified Nov 17, 2026: no FDA-approved sermorelin product is marketed; it appears in no category of the FDA's 503A nominated bulks document (list updated May 14, 2026), is not named in 21 CFR 216.23, and is not one of the six peptides under the October 2026 HHS enforcement-discretion policy; compounded sermorelin is not FDA-approved, and its compounding rests on its history as a component of a formerly approved drug withdrawn for non-safety reasons.

Changelog

Last updated 2026-11-17

  • 2026-11-17|Record created. Evidence D on a pediatric-weighted file with no adult outcome trials; worth-it D at a swept telehealth cost of $100 to $300 a month. Regulatory position verified against the FDA 503A nominated bulks document (May 14, 2026 list) at drafting: sermorelin appears in no category and holds no interim status.

The week's longevity and biohacking news.

Every story graded against the evidence. Free. Unsubscribe anytime.

The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.

Every grade follows a published rubric. Sponsors do not influence findings or grades.